Sage Therapeutics Inc (NASDAQ:SAGE) shares, rose in value, with the stock price up by 1.28% to the previous day’s close as strong demand from buyers drove the stock to $20.61.
Actively observing the price movement in the last trading, the stock closed the session at $20.35. The value of beta (5-year monthly) was 0.93. Referring to stock’s 52-week performance, its high was $59.99, and the low was $16.51. On the whole, SAGE has fluctuated by -13.51% over the past month.
With the market capitalization of Sage Therapeutics Inc currently standing at about $1.24 billion, investors are eagerly awaiting this quarter’s results, scheduled for Apr 30, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$1.6, which is expected to increase to -$0.86 for fiscal year -$6.22 and then to about -$4.76 by fiscal year 2025. Data indicates that the EPS growth is expected to be 31.30% in 2025, while the next year’s EPS growth is forecast to be 23.50%.
Analysts have estimated the company’s revenue for the quarter at $5.9 million, with a low estimate of $2.12 million and a high estimate of $15.08 million. According to the average forecast, sales growth in current quarter could jump up 144.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $37.7 million, representing a decrease of -56.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that SAGE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of SAGE currently trading nearly -7.67% and -13.82% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.39, while the 7-day volatility ratio is showing 4.36% which for the 30-day chart, stands at 5.02%. Furthermore, Sage Therapeutics Inc (SAGE)’s beta value is 0.87, and its average true range (ATR) is 1.04.
A comparison of Sage Therapeutics Inc (SAGE) with its peers suggests the former has fared considerably weaker in the market. SAGE showed an intraday change of 1.28% in last session, and over the past year, it shrunk by -52.47%%.
Data on historical trading for Sage Therapeutics Inc (NASDAQ:SAGE) indicates that the trading volumes over the past 10 days have averaged 0.79 million and over the past 3 months, they’ve averaged 961.60K. According to company’s latest data on outstanding shares, there are 60.04 million shares outstanding.
Nearly 18.39% of Sage Therapeutics Inc’s shares belong to company insiders and institutional investors own 94.75% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 7.91 million shares as on Feb 29, 2024, resulting in a short ratio of 7.34. According to the data, the short interest in Sage Therapeutics Inc (SAGE) stood at 13.16% of shares outstanding as of Feb 29, 2024; the number of short shares registered in Jan 31, 2024 reached 7.86 million. The stock has fallen by -4.89% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SAGE stock heading into the next quarter.
